Learn about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), and bullous pemphigoid, (BP), and which cytokines play key roles in driving this activity.
Explore a treatment option for appropriate patients with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU), orbullous pemphigoid, (BP) through patient perspectives.
©2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. [US DER #]